Capital increase in connection with exercise of warrants

In December 2013, Ambu A/S issued 2,000,000 warrants and in December 2014 2,000,000 warrants, each warrant entitling the holder to subscribe for one Class B share with a nominal value of DKK 0.50. 52 individuals participate in the 2013 scheme and 22 individuals participate in the 2014 scheme. In both cases, the vesting period is three years, and both schemes can therefore be exercised in the trading window that opened on 23 August in connection with Ambu’s interim financial report for Q3 2017/18.

Since 23 August 2018, instructions have been received to exercise warrants as follows:

- 2013 scheme: One individual has issued instructions to exercise a total of 50,000 warrants at the agreed exercise price of DKK 13.26 per share with a nominal value of DKK 0.50.
- 2014 scheme: Three individuals have issued instructions to exercise a total of 200,000 warrants at the agreed exercise price of DKK 23.06 per share with a nominal value of DKK 0.50.

Today Ambu’s Board of Directors decided to carry out the capital increase relating to the exercised warrants.

As a result of the capital increase, the share capital of Ambu will be increased by a nominal amount of DKK 125,000 from DKK 125,512,300 to DKK 125,637,300 through the issue of 250,000 Class B shares.

Following this and in consideration of the employees having left the company, there are 150,000 remaining warrants under the 2013 scheme being held by five individuals and 600,000 remaining warrants under the 2014-scheme being held by eight individuals.

The new B shares are expected to be admitted to trading and official listing on NASDAQ Copenhagen A/S on 6 September 2018 under the ISIN code of Ambu A/S’ existing B shares (DK0060946788).

Under section 10 of the Danish Executive Order on disclosure requirements for issuers, Ambu A/S is to announce the total share capital and the total voting rights by the end of a month in which any change of the share capital was effected. The table below shows the total share capital and the total voting rights of Ambu A/S after the capital increase.

<table>
<thead>
<tr>
<th></th>
<th>Number of shares (nominal value DKK 0.50)</th>
<th>Nominal value (DKK)</th>
<th>Voting rights</th>
</tr>
</thead>
<tbody>
<tr>
<td>A shares</td>
<td>34,320,000</td>
<td>17,160,000</td>
<td>343,200,000</td>
</tr>
<tr>
<td>B shares</td>
<td>216,954,600</td>
<td>108,477,300</td>
<td>216,954,600</td>
</tr>
<tr>
<td>Total</td>
<td>251,274,600</td>
<td>125,637,300</td>
<td>560,154,600</td>
</tr>
</tbody>
</table>
Contact
Lars Marcher, President & CEO, tel. +45 5136 2490, email: lm@ambu.com

About Ambu
Since 1937, breakthrough ideas have fuelled our work on bringing efficient healthcare solutions to life. This is what we create within our fields of excellence – Anaesthesia, Patient Monitoring & Diagnostics, and Emergency Care. Millions of patients and healthcare professionals worldwide depend on the functionality and performance of our products. We are dedicated to improve patient safety and determined to advance single-use devices. The manifestations of our efforts range from early inventions like the Ambu Bag™ resuscitator and the legendary BlueSensor™ electrodes to our newest landmark solutions like the Ambu aScope™ – the world’s first single-use flexible endoscope. Our commitment to bringing new ideas and superior service to our customers has made Ambu one of the most recognized medtech companies in the world. Headquartered near Copenhagen in Denmark, Ambu employs approximately 2,700 people in Europe, North America and the Asia Pacific. For more information, please visit www.ambu.com.